Stocktoria
Incannex Healthcare Inc. IXHL
Incannex Healthcare Inc. (IXHL) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $86,000 at a -54517.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
FAQ
Is IXHL financially healthy?
Incannex Healthcare Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does IXHL pay a dividend?
No, Incannex Healthcare Inc. does not currently pay a dividend.
How profitable is IXHL?
In FY2025, Incannex Healthcare Inc. had a net margin of -54517.4% and a return on equity of -350.2%.
What is the analyst price target for IXHL?
The average Wall-Street price target for Incannex Healthcare Inc. is $17.57, about 454.3% above the recent price, from 1 analysts (consensus: strong buy).
Is IXHL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Incannex Healthcare Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.